Celiac Disease Diagnostics Market Size, Share and Forecast 2032

Market Overview

The Celiac Disease Diagnostics Market is projected to grow from USD 307.3 million in 2024 to USD 568.79 million by 2032, registering a robust compound annual growth rate (CAGR) of 8% during the forecast period.

The Celiac Disease Diagnostics Market is driven by the increasing prevalence of celiac disease worldwide, coupled with rising awareness about the condition and its potential complications. Improved healthcare infrastructure and advancements in diagnostic technologies, such as serological tests and genetic screening, have significantly enhanced early detection and management of the disease. The growing focus on personalized medicine and the adoption of non-invasive diagnostic methods are further boosting market growth. Additionally, supportive government initiatives and healthcare policies promoting early diagnosis and treatment of autoimmune disorders are propelling demand for diagnostic solutions. Trends in the market include the development of advanced point-of-care testing devices, enabling faster and more convenient detection of celiac disease. The integration of artificial intelligence and machine learning in diagnostic tools is also gaining traction, offering improved accuracy and predictive capabilities. These factors collectively contribute to the market’s expansion and underscore its importance in modern healthcare.

The Celiac Disease Diagnostics Market exhibits significant geographical diversity, with North America leading the market, holding 42% of the global share in 2024, driven by advanced healthcare infrastructure and high disease awareness. Europe follows with 35% market share, supported by strict gluten-free labeling regulations and strong healthcare initiatives in countries like Italy, Germany, and the UK. Asia-Pacific, accounting for 15%, is witnessing rapid growth due to increasing awareness and rising healthcare investments in China, India, and Japan. The Rest of the World, including Latin America, the Middle East, and Africa, holds 8%, with growth fueled by emerging healthcare infrastructure and public health campaigns. Key players shaping the market include Amgen Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Viatris Inc., among others.

Market Insights

• The Celiac Disease Diagnostics Market is projected to grow from USD 307.3 million in 2024 to USD 568.79 million by 2032, with a robust CAGR of 8% during the forecast period.
• The market is driven by the increasing prevalence of celiac disease and greater awareness of its complications.
• Advancements in serological tests, genetic screening, and point-of-care technologies have enhanced diagnostic accuracy and efficiency.
• The integration of artificial intelligence (AI) and machine learning (ML) is improving diagnostic tools by enhancing accuracy and predictive capabilities.
• North America leads the market, holding 42% of the global share in 2024, followed by Europe at 35%, supported by robust healthcare infrastructure.
• Asia-Pacific holds 15% market share in 2024, with growth driven by rising awareness, healthcare investments, and demand for advanced diagnostics.
• Key challenges include limited awareness, underdiagnosis, and high costs of advanced diagnostics, particularly in low-income regions, necessitating affordable solutions.

Market Drivers

Increasing Prevalence of Celiac Disease

The rising prevalence of celiac disease globally is a significant driver of the Celiac Disease Diagnostics Market. With increasing awareness about the disease, more individuals are seeking medical diagnosis, leading to higher demand for accurate and reliable diagnostic solutions. For instance, a study by the National Institute of Health highlighted the growing incidence of autoimmune disorders, which underscores the need for early and precise detection, bolstering market growth. Research indicates a growing incidence of autoimmune disorders, including celiac disease, due to factors such as genetic predisposition, lifestyle changes, and dietary habits.

Advancements in Diagnostic Technologies

Technological advancements in diagnostic tools have significantly enhanced the accuracy and efficiency of detecting celiac disease. For example, Quest Diagnostics has introduced next-generation serological tests that reduce diagnostic time and improve patient outcomes, making these advancements essential drivers of market expansion. Innovations such as next-generation serological tests, genetic screening methods, and point-of-care testing devices enable healthcare professionals to diagnose the disease more effectively.

Growing Focus on Personalized Medicine

The increasing emphasis on personalized medicine is another key driver for the market. Personalized approaches enable tailored diagnostic and therapeutic interventions for celiac disease, improving treatment efficacy. For instance, Myriad Genetics provides genetic testing solutions that support individualized care, including genetic testing and biomarker identification, which aligns with the broader trend of precision healthcare and further fuels market growth.

Supportive Government Policies and Awareness Initiatives

Government initiatives and awareness campaigns aimed at promoting early diagnosis and management of celiac disease are playing a crucial role in driving market growth. Policies supporting research and development in autoimmune disease diagnostics, coupled with subsidies and funding for advanced diagnostic tools, have created a favorable environment for market expansion. For example, the European Commission has implemented policies that support research and development in autoimmune disease diagnostics. Public health campaigns emphasizing the importance of early detection have also contributed to increased utilization of diagnostic services. These initiatives collectively enhance market penetration and accessibility.

 Market Trends

Rising Adoption of Non-Invasive Diagnostic Methods

A significant trend in the Celiac Disease Diagnostics Market is the increasing preference for non-invasive diagnostic methods. Techniques such as serological tests, which include anti-tissue transglutaminase (tTG) and anti-endomysial antibody (EMA) tests, have become widely used due to their convenience and high accuracy. For instance, Prometheus Laboratories Inc. offers advanced serological testing devices that enhance patient comfort and compliance. These methods eliminate the need for invasive biopsies in many cases, improving patient comfort and compliance. The development of innovative point-of-care testing devices is further accelerating this trend.

Integration of Advanced Technologies

The integration of advanced technologies, such as artificial intelligence (AI) and machine learning (ML) is reshaping the diagnostic landscape. AI-powered tools enable precise analysis of complex datasets, aiding in early detection and reducing the likelihood of misdiagnosis. For instance, AI-based diagnostic tools developed by Quest Diagnostics are enhancing the precision and efficiency of celiac disease diagnosis. Machine learning algorithms are also being employed to predict disease progression and outcomes, enhancing the personalization of diagnostic approaches. These advancements are expected to drive innovation and efficiency in the market.

Growing Emphasis on Genetic Testing

Genetic testing is gaining prominence as a reliable diagnostic tool for celiac disease.  Tests that identify specific genetic markers, such as HLA-DQ2 and HLA-DQ8, are being increasingly utilized to confirm diagnoses and rule out false positives. For instance, Myriad Genetics offers genetic testing for celiac disease to confirm diagnoses and enhance patient outcomes. The growing focus on understanding genetic predisposition to celiac disease aligns with the broader trend of precision medicine, enabling targeted interventions and improved patient outcomes.

Increasing Awareness and Accessibility

Awareness campaigns and improved accessibility to diagnostic solutions are pivotal trends shaping the market. Public health initiatives aimed at educating individuals about celiac disease symptoms and the importance of early diagnosis are increasing the uptake of diagnostic services. For instance, the National Celiac Association's awareness campaigns have significantly increased the uptake of diagnostic services. Simultaneously, the expansion of diagnostic centers and the availability of affordable testing solutions are improving access, especially in emerging economies, contributing to market growth.

Market Challenges Analysis

Limited Awareness and Underdiagnosis

One of the primary challenges in the Celiac Disease Diagnostics Market is the limited awareness and significant underdiagnosis of the condition. Despite growing recognition, many individuals remain undiagnosed due to a lack of awareness among patients and healthcare providers about the symptoms and potential severity of celiac disease. In some regions, particularly in emerging economies, awareness campaigns and educational efforts are inadequate, further exacerbating this issue. Misdiagnosis is also common due to overlapping symptoms with other gastrointestinal disorders, delaying appropriate interventions and increasing the risk of long-term complications. This gap in awareness and diagnosis limits the market’s potential growth and underscores the need for broader educational initiatives, enhanced training for healthcare providers, and improved diagnostic protocols to bridge these critical gaps effectively.

High Costs and Accessibility Barriers

The high costs associated with advanced diagnostic tools and procedures pose another challenge to the Celiac Disease Diagnostics Market. While technologies such as genetic testing and advanced serological assays offer superior accuracy, their affordability remains a concern, particularly in low-income and underdeveloped regions. Additionally, limited access to diagnostic facilities in rural and remote areas creates disparities in healthcare delivery, leaving a significant portion of the population underserved and at risk of prolonged illness. The lack of insurance coverage or reimbursement policies for diagnostic procedures further compounds this issue, deterring individuals from seeking timely diagnosis. These barriers hinder the adoption of diagnostic solutions, particularly in resource-constrained settings, and highlight the importance of developing cost-effective and scalable diagnostic technologies. Collaborative efforts between governments, healthcare organizations, and diagnostic companies are essential to improve affordability, accessibility, and equity in celiac disease diagnostics across diverse populations.

Market Segmentation Analysis:

By Treatment

The Celiac Disease Diagnostics Market is segmented by treatment into dietary management and pharmacological interventions. Dietary management, particularly adherence to a strict gluten-free diet, remains the cornerstone of treatment. Emerging pharmacological treatments, including enzyme therapies and immunomodulators, are gaining traction as complementary solutions to address residual symptoms and improve patient outcomes.

By Route of Administration

Based on the route of administration, the market includes oral and parenteral options. Oral diagnostics and treatments, such as enzyme supplements, are preferred for their convenience and patient compliance. Parenteral options, including injectables, are primarily utilized in severe cases or for addressing associated conditions, providing healthcare providers with versatile approaches for managing the disease effectively.

By Distribution Channel

The distribution channel segment comprises hospital pharmacies, retail pharmacies, and online platforms. Hospital pharmacies dominate due to the increasing prevalence of in-hospital diagnostics and treatments. Meanwhile, online platforms are witnessing rapid growth, driven by convenience, wider product availability, and the growing adoption of e-commerce in healthcare.

Segments:

Based on Treatment

• Vitamins & Minerals
• Gluten-free Diet
• Medical Therapies
• Infliximab
• Larazotide Acetate
• Azathioprine
• Budesonide
• Others

Based on Route of Administration

• Oral
• Parenteral

Based on Distribution Channel

• Hospitals
• Research Centers
• Others

Based on the Geography:

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Regional Analysis

North America

North America holds a dominant position in the Celiac Disease Diagnostics Market, accounting for 42% of the global market share in 2024. The region's leadership is attributed to the high prevalence of celiac disease, advanced healthcare infrastructure, and increased awareness about the condition. The U.S. is the primary contributor, supported by significant investments in research and development of diagnostic solutions, including genetic testing and serological assays. Canada also plays a vital role, with growing initiatives to educate healthcare providers and patients about early diagnosis and management. The availability of advanced diagnostic technologies and favorable reimbursement policies further strengthen the market in North America.

Europe

Europe represents 35% of the global market share in 2024, making it the second-largest region in the Celiac Disease Diagnostics Market. The region benefits from a high prevalence of celiac disease, particularly in countries like Italy, the United Kingdom, and Germany, where gluten-related disorders are widely recognized. Strict regulations on gluten-free labeling and increased government funding for healthcare research contribute to the region's market growth

Asia-Pacific

Asia-Pacific accounted for 15% of the global market share in 2024, driven by increasing awareness and improved healthcare access. While the region's share is smaller compared to North America and Europe, its growth potential is immense due to rising diagnostic demand in countries like China, India, and Japan. Investments in healthcare infrastructure and increasing patient awareness about the condition are fueling market growth.

Rest of the World

The Rest of the World, including Latin America, the Middle East, and Africa, accounted for 8% of the global market share in 2024. While smaller in size, these regions are gradually adopting advanced diagnostic methods due to increased healthcare investments and public health initiatives. Efforts to improve awareness and accessibility are expected to drive long-term growth in these regions, positioning them as emerging contributors to the global market.

Key Player Analysis

• Amneal Pharmaceuticals LLC
• Takeda Pharmaceutical Company Limited
• Zydus Pharmaceuticals, Inc.
• Amgen Inc.
• Hikma Pharmaceuticals PLC
• BioLineRx Ltd.
• Glenmark Life Sciences Limited
• Viatris Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.

Competitive Analysis

The Celiac Disease Diagnostics Market is characterized by intense competition among leading players, driven by advancements in diagnostic technologies and expanding global demand. Companies such as Teva Pharmaceutical Industries Ltd., Amgen Inc., Amneal Pharmaceuticals LLC, Glenmark Life Sciences Limited, Takeda Pharmaceutical Company Limited, Hikma Pharmaceuticals PLC, Viatris Inc., Zydus Pharmaceuticals, Inc., Novartis AG, and BioLineRx Ltd. leverage their robust R&D capabilities to innovate and enhance diagnostic tools, including serological tests, genetic screening, and point-of-care solutions. For instance, Thermo Fisher Scientific Inc. recently launched a new serological testing kit that offers improved accuracy and ease of use for diagnosing celiac disease. These players focus on strategic collaborations, product launches, and geographic expansions to strengthen their market presence. The competitive landscape is further defined by efforts to reduce costs, improve diagnostic accuracy, and increase accessibility in underserved regions. By addressing market challenges such as high costs and limited awareness, these companies aim to capture a larger share of the rapidly growing market.

Recent Developments

• In February 2024, Novartis received the FDA approval of Xolair (omalizumab) as the first and only medication for reducing allergic reactions in individuals aged one and older with IgE-mediated food allergies. This approval followed the successful Phase III OUtMATCH study, demonstrating that Xolair significantly helps patients tolerate small amounts of allergens including peanuts and milk.
• In May 2023, Topas Therapeutics treating Autoimmune Celiac disease with TPM502. It is expected that a double-blind, placebo-controlled, multicenter trial intended for a randomized phase ĩ, which would analyze the safety, tolerability and pharmacodynamic consequences of two dose-escalating administrations of TPM502 to different cohorts is anticipated.
• In May 2023, Anokion has announced positive results from a completed Phase I trial examining KAN-101 as a treatment for celiac disease. The ACeD trial was a randomized, double-blind, placebo-controlled investigation of gluten-free diets in 41 individuals with celiac disease across two cohorts of single-ascending dose and multi-ascending dose. Early study results demonstrated the safety and tolerability of KAN-101, as well as the induction of functional tolerance in gliadin-specific T cells in response to gluten challenge. Unlike conventional broad-spectrum immunosuppressants, KAN-101 can specifically target immune system components responsible for gluten-related immune reactions.
• In April 2023, Innate Pharma signed an exclusive licensing agreement with Takeda, which gives Takeda worldwide rights to study and develop antibody-drug conjugates against an anonymous target, notably Celiac disease.

Market Concentration & Characteristics

The Celiac Disease Diagnostics Market is moderately fragmented, with a mix of global and regional players competing to gain market share. Leading companies, such as Teva Pharmaceutical Industries Ltd., Amgen Inc., and Takeda Pharmaceutical Company Limited, dominate the market with their strong portfolios of advanced diagnostic tools, including serological tests and genetic screening solutions. The market is characterized by continuous innovation, driven by advancements in technologies such as point-of-care testing devices and the integration of artificial intelligence (AI) for improved diagnostic accuracy. Regional players contribute significantly by catering to localized needs and offering cost-effective solutions. The market also demonstrates a strong focus on personalized medicine, emphasizing tailored diagnostic approaches. While North America and Europe lead in market share due to advanced infrastructure and awareness, growing investments in healthcare are bolstering expansion in Asia-Pacific and other emerging regions, reflecting the market's global growth potential.

Report Coverage

The research report offers an in-depth analysis based on Treatment, Route of Administration, Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

1. The Celiac Disease Diagnostics Market is expected to witness robust growth with a projected CAGR of 8% from 2024 to 2032.
2. Increasing prevalence of celiac disease will drive demand for advanced diagnostic solutions globally.
3. Technological advancements, including point-of-care testing and AI-powered diagnostics, will improve accuracy and efficiency.
4. Non-invasive diagnostic methods, such as serological and genetic testing, will gain widespread adoption.
5. Personalized medicine approaches will become a key focus, enabling tailored diagnostic and treatment strategies.
6. North America will maintain its leadership due to advanced healthcare infrastructure and high disease awareness.
7. Europe will experience steady growth, supported by strict gluten-free labeling regulations and healthcare initiatives.
8. Asia-Pacific will emerge as a high-growth region due to rising awareness and healthcare investments.
9. Efforts to address underdiagnosis and increase affordability will enhance market accessibility, especially in underserved regions.
10. Strategic collaborations and innovation by key players will shape the competitive landscape and market expansion.

Increasing Prevalence of Celiac Disease

The global rise in celiac disease cases, driven by genetic predisposition and changing dietary habits, is leading to greater demand for diagnostic solutions as more individuals seek medical evaluation for related symptoms.

Advancements in Diagnostic Technologies

Innovations in serological tests, genetic screening, and point-of-care devices have improved the accuracy, speed, and accessibility of celiac disease diagnosis, encouraging broader adoption by healthcare providers.

Growing Focus on Personalized Medicine

The shift toward personalized medicine enables tailored diagnostic and therapeutic approaches for celiac disease, improving patient outcomes and driving demand for advanced, individualized diagnostic tools.

Supportive Government Policies and Awareness Initiatives

Government-backed awareness campaigns and funding for autoimmune disease diagnostics are increasing early detection rates and expanding access to diagnostic services, particularly in developed regions.

Rising Adoption of Non-Invasive and AI-Integrated Diagnostics

The market is benefiting from the trend toward non-invasive serological and genetic tests, as well as the integration of artificial intelligence and machine learning, which enhance diagnostic accuracy and efficiency.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.